Who will own psilocybin for anorexia?

One of the methods claimed in Compass’ PCT application is administering “a therapeutically-effective dose of psilocybin” to a subject with anorexia

Could a claim on treating anorexia with psilocybin be granted?

1/7
Compass is listed as collaborator on an investigator-initiated study at UC San Diego, to explore the safety, tolerability, & efficacy of psilocybin-assisted therapy for anorexia

This trial was first posted on December 10, 2020

2/7

clinicaltrials.gov/ct2/show/NCT04…
Another study, sponsored by Imperial College London, will also assess the acceptability & efficacy of treating anorexia with psilocybin, & will use MRI & EEG to examine neuronal underpinnings of tx

This trial was posted earlier, on August 10, 2020

3/7

clinicaltrials.gov/ct2/show/NCT04…
A third study, sponsored by Johns Hopkins University, is an open-label pilot investigating the safety & efficacy of psilocybin in anorexia

This trial was posted earliest, on August 12, 2019

4/7

clinicaltrials.gov/ct2/show/NCT04…
Compass’ PCT application has a priority date based on the filing of its first US provisional

The priority date is April 17, 2019

If that date is before Johns Hopkins’ & Imperial College London’s trials became public, would they not be prior art?

5/7

patents.google.com/patent/WO20202…
As @ericarex has written, an inpatient in a Paris psychiatric hospital was given psilocybin to treat her anorexia in 1959

This was documented in a 1960 French doctoral dissertation: “La Psilocybine en psychiatrie clinique et expérimentale“

6/7

psychedelicrenaissance.substack.com/p/psilocybin-t…
How would a 1960 French doctoral dissertation come to the attention of a patent examiner?

If it didn’t, could a claim on treating anorexia w psilocybin be granted?

If a claim was granted, what would happen to research at Johns Hopkins & Imperial?

7/7

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Graham Pechenik

Graham Pechenik Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @calyxlaw

21 Mar
New Compass Pathways patents granted?

Another US patent was granted on March 16, 2021

This is Compass’ second US patent, in same family as the first patent granted on December 31, 2019

New ‘257 patent: patft.uspto.gov/netacgi/nph-Pa…

First ‘175 patent: patft.uspto.gov/netacgi/nph-Pa…

1/7 Image
A primary difference between the new ‘257 & the first ‘175 patent is:

– ‘175 patent claims methods “of treating drug resistant depression” by orally administering “an oral dosage form“ of the COMP360 psilocybin Polymorph A

– ‘257 patent claims the “oral dosage form” itself

2/7 ImageImage
Just as with the first ‘175 patent, the new ‘257 patent claims the psilocybin Polymorph A by reference to its “XRPD diffractogram”

These are the peaks displayed when the polymorph is analyzed by X-ray

Compass unsuccessfully sought claims without these XRPD limitations

3/7
Read 7 tweets
18 Feb
How much is a psilocybin patent application worth?

PharmaTher $PHRM sells psilocybin program to Revive Therapeutics $RVV

Includes full rights to PharmaTher’s psilocybin IP:

Pre-clinical work + three psilocybin provisional applications

1/4
Purchase price for PharmaTher’s psilocybin IP:

–$3 million in cash

–$4 million in securities

–up to $3 million in milestone payments

–“low single digit royalty” on future net sales

2/4
More on PharmaTher’s:

Psilocybin combination therapies:

Psilocybin in treatment of cancer:

Microneedle delivery technology, which it retains after the sale:

3/4
Read 4 tweets
17 Feb
“Emergency Off-Switch” for psychedelics?

MindMed $MMED beings study on “LSD neutralizer technology”

I.e., the 5-HT2A antagonist ketanserin: psychedelicreview.com/compound/ketan…

1/4
Patent application first announced on April 21, 2020

As @psyscireview subsequently wrote: “Few Details of the Invention Are Available”

18 months after filing, the application—& those details—will become public

~ October 2021

psychedelicreview.com/stopping-bad-l…

2/4
“LSD neutralizer technology”—is it possible, patentable, profitable?

Last year, from @D__Nickles: psymposia.com/magazine/rahn-…

Today, more insights from @mattbagg:

3/4
Read 4 tweets
16 Feb
Controlled release psilocybin + cannabinoid formulations?

New published patent application on multilayer tablets & capsules w psilocybe-derived + cannabis-derived compounds

Filed by Tassili Life Sciences, acquired last yr by Champignon Brands

patentscope.wipo.int/search/en/deta… $SHRM

1/ ImageImageImage
Application claims compositions of “psilocybe-derived agent and a cannabis-derived agent”

”formulated in multiple layers to release the psilocybin-derived agent and the cannabis-derived agent at multiple different times, dosages and/or locations in a subject during dosing”

2/ Image
Application asserts controlled release formulations of psilocybin + CBD can result in “multiple chemical-induced high/low shocks”

"useful in eliciting short or long term traumatic experience suppression in similar fashion to electroshock therapy without memory eradication”

3/ ImageImage
Read 6 tweets
23 Dec 20
Canopy Growth sues GW Pharmaceuticals:

Complaint for patent infringement filed on 12/22 in Texas

“This dispute relates to GW’s continued, unauthorized use of Canopy’s patented processes for extracting cannabidiol from cannabis plant material.”

1/

$CGC $GWPH #cannabispatents
Canopy alleges infringement of one patent:

US Patent No. 10,870,632 “Process For Producing An Extract Containing Tetrahydrocannabinol And Cannabidiol From Cannabis Plant Material, And Cannabis Extracts”

Patent issued 12/22—same day complaint filed

pdfpiw.uspto.gov/.piw?Docid=108…

2/
Canopy got the patent in its acquisition of Germany’s C3 Cannabinoid Compound Company, founded by herbal medicine manufacturer Bionorica SE

It is part of a patent family dating back to a German application filed on October 17, 2000

It relates to CO2 extraction of THC & CBD

3/
Read 9 tweets
17 Dec 20
Deuterated DMT analogs?

New patent application by Small Pharma published today.

The “invention provides compositions and methods which enable a finely tuned single dose to maintain a patient in full dissociation from the external world, referred to herein as ‘DMT space.’”

1/ Image
In particular, the invention takes advantage of “the kinetic isotope effect” exhibited by deuterated DMT analogs “in order to modify, controllably, the pharmacokinetic profile of N,N-DMT, thereby permitting more flexible therapeutic application.”

pdfaiw.uspto.gov/.aiw?PageNum=0…

2/ Image
“Deuterated” means that one or more hydrogen atoms in DMT are replaced by its heavier stable isotope deuterium. Because of the “kinetic isotope effect,” deuterated drugs may have significantly lower rates of metabolism and a longer half-life.

en.wikipedia.org/wiki/Deuterate…

3/ Image
Read 9 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!